GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the second quarter of 2026, highlighting continued progress toward the planned initiation of a pivotal immunobridging study for its vaccine candidate GEO-MVA. The clinical-stage biotechnology company is pursuing an expedited regulatory pathway for GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, following scientific advice from the European Medicines Agency (EMA).
The company expects to launch the pivotal study in the fourth quarter of 2026, aiming to demonstrate non-inferiority to an approved MVA vaccine. CEO David A. Dodd emphasized the strategic importance of this milestone, stating that GEO-MVA addresses the growing global need for diversified MVA vaccine supply to support public health preparedness and biodefense. GeoVax has already manufactured and released cGMP clinical trial material and is advancing the AGE1 continuous cell-line manufacturing platform for future commercial-scale production.
GeoVax’s decision to prioritize GEO-MVA and its immuno-oncology candidate Gedeptin led to the discontinuation of active development for its GEO-CM04S1 COVID-19 vaccine. The company cited the contraction of the global COVID-19 vaccine market and a focus on programs with clearer regulatory pathways and commercialization potential. No safety or efficacy concerns prompted the move.
The Gedeptin program is being positioned as a combination therapy with immune checkpoint inhibitors like Merck’s Keytruda. GeoVax holds an exclusive license from Emory University for this combination strategy, which aims to enhance responsiveness in immunologically resistant solid tumors.
Financially, GeoVax reported a net loss of $4.4 million for the second quarter of 2026, or $0.97 per share, compared to a net loss of $5.4 million, or $8.74 per share, in the same period last year. The reduction in loss was partly due to lower research and development expenses, which decreased to $3.1 million from $4.7 million, reflecting the wind-down of COVID-19 activities. General and administrative expenses also fell to $1.3 million from $1.5 million. The company ended the quarter with approximately $3.1 million in cash, unchanged from year-end 2025.
GeoVax’s strategic reprioritization, announced in May 2026, concentrates resources on GEO-MVA and Gedeptin. The company believes GEO-MVA is uniquely positioned to help address the need for diversified global MVA vaccine manufacturing capacity, supporting public health preparedness and biodefense resilience. Engagement with government and international stakeholders is ongoing to secure future procurement opportunities.
The advancement of GEO-MVA under an expedited regulatory pathway could provide an additional supplier of MVA vaccines, which are critical for orthopoxvirus preparedness. This development comes as global health authorities continue to emphasize the importance of maintaining robust vaccine supplies against potential outbreaks of mpox and smallpox.
For more information, visit the company’s website at www.geovax.com.
